



Figure 2: PRISMA flow of studies through the SLR

Prognostic and Risk Factors of Psoriatic Arthritis among Adult Psoriasis Patients in the United States: A Systematic Literature Review

Gunjan Bisht¹, Ritesh Dubey¹, Sumeet Attri¹, Pankaj Rai¹, Gagandeep Kaur¹, Barinder Singh² ¹Pharmacoevidence, Mohali, India, ²Pharmacoevidence, London, UK

ributing to PsA in t	he	US, wi	th nota	ble associa	tions
	>	Gender:	Women e	exhibited a highe	er susce
ory disease affecting the joint impairment and			Study name Merola 2023 Ogdie 2019	Risk factor Males vs Females Males vs Females	
uting to the onset or			Study name	Risk factor	.9
			CI: Confidence Inter	rval; HR: Hazard ratio, OR: Odds ratio	
orognostic or risk factors es (US)	>	Comorb i significar	idities: (Coronary artery	/ disea / disea factors
I databases (EMBASE [®] ween January 2012 and			Yan 2018 Yan 2018 Yan 2018 Yan 2018 Yan 2018 Yan 2018 Yan 2018	Hypertension Diabetes, type 2 Hypercholesterolemia Hypertriglyceridemia Coronary artery disease Stroke	
factors of PsA. The			Study name Belman 2021	.125 Risk factor (yes vs. no) High blood pressure	
third reviewer resolved			Belman 2021 Belman 2021 Belman 2021 Belman 2021 Belman 2021	Stroke High cholesterol Diabetes Myocardial infraction Depression	
tervention and comparator orestriction			Belman 2021 Belman 2021 Belman 2021 Belman 2021 Belman 2021 Belman 2021 Wu 2014 Belman 2021	Inflammatory bowel disea Asthma Smoker Eczema Cancer High cholesterol Hypercholesterolemia Fingernail involvement	ise
		- C	Belman 2021	History of scalp PsO .0312 ; HR: Hazard ratio, OR: Odds ratio, Ps	2 5 sO: Psoriasis
o restriction	>	F Age: The	Figure 4: For e risk of d	est plot for comorbid eveloping PsA ir	ity as a ris
		0	Study name	Risk factor	
			Merola 2022 Merola 2022 Merola 2022 Merola 2023 Merola 2023 Merola 2023 Merola 2023	Age: 25-34 vs. ≥65 Age: 35-44 vs. ≥65 Age: 45-54 vs. ≥65 Age: 55-64 vs. ≥65 Age: 30-39 vs. 18-29 Age: 40-49 vs. 18-29 Age: 50-59 vs. 18-29 Age: 60-69 vs. 18-29	
			CI: Confidence Interv Figure 5: Fc	.5 val; HR: Hazard ratio prest plot for age as a	risk facto
Figure 2 the prognostic and risk ed from 128 to 85.324		Psoriasis of sever	s severit e psoria _{Study name}	y: The risk of sis (Figure 6) Risk factor (PsC vs. PsA	develo
			Belman 2021 Belman 2021 Belman 2021 Belman 2021 Belman 2021 Belman 2021	Untreated induration Untreated desquamation Untreated erythema Induration at enrollment Desquamation at enrollment Erythema at enrollment	ent
opy duplicate (n=15)			Study name	Risk factor (PsA vs. No	.667 PsA)
ublications excluded (n=166) editorial (n=19) only (n=04) (n=48) e (n=87)			Yan 2018 Yan 2018 Yan 2018 Yan 2018	Mild Mild-moderate Severe-Moderate Severe	• •
ear (n=05) sign (n=03) ublications excluded			CI: Confidence interv Figure 6: Fo	.25 val; HR: Hazard ratio, OR: Odds ratio, prest plot for psoriasi	PsA: Psoriatic a S Severity
(n=04) (n=01) (n=01) ne (n=02)	70,00	Refe	rence	Li T, Cho E. Gluten intake and risk o	f psoriasis, psori
		2014 Feb;66(2):304-1 Associated with the De Patil D, Richardson C Takeshita J, Choi H, L women. Annals of the	0; 3.Tong LX, Wu S, evelopment of Psoriati , Scott A, Chen YH, K ove TJ, Ritchlin CT, G rheumatic diseases. 2	Li T, Qureshi AA, Giovannucci EL, Cl ic Arthritis: Retrospective Analysis of a im N, Hur P, Armstrong AW. Incidence Gelfand J, Merola JF. OP0115 GENER 2012 Aug 1;71(8):1267-72; 10. Yan D,	ho E. Personal h a US Claims Data a and prevalenc AL AND SEX-SI Ahn R, Leslie S,

Presented at ISPOR 2024 | Atlanta, Georgia | US May 5-8, 2024



iatic arthritis, and atopic dermatitis among United States women. Journal of the American Academy of Dermatology. 2020 Mar 1;82(3):661-5; 2. Wu S, Li WQ, Han J, Sun Q, Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis & Rheumatology. nistory of gallstones and risk of incident psoriasis and psoriatic arthritis in US women. British Journal of Dermatology. 2015 May 1;172(5):1316-22; 4. Merola JF, Patil D, Egana A, Steffens A, Webb NS, Gottlieb AB. Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors abase. Dermatology and Therapy. 2023 Nov;13(11):2635-48; 5. Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ. Psoriasis characteristics for the early detection of psoriatic arthritis. The Journal of rheumatology. 2021 Oct 1;48(10):1559-65; 6. Merola JF, Tian H, ce of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States. Journal of the American Academy of Dermatology. 2022 Apr 1;86(4):748-57; 7. Ogdie A, Scher J, Wang SV, Shin D, Margolis D, PECIFIC PREDICTORS OF PSA AMONG PATIENTS WITH PSORIASIS; 8. Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Annals of the rheumatic diseases. 2012 Jun 1;71(6):804-8; 9. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US Liao W. Clinical and genetic risk factors associated with psoriatic arthritis among patients with psoriasis. Dermatology and therapy. 2018 Dec;8:593-604



For further queries, please contact: barinder.singh@pharmacoevidence.com

EPH46



yes vs. no)		OR (95% CI)
of psoriasis		1.17 (0.83, 1.66)
ment	◆	2.09 (1.28, 3.43)
ent	→	1.40 (0.98, 2.01)
nvolvement	→	1.62 (1.04, 2.53)
vement	◆	1.16 (0.70, 1.91)
ment	→	1.38 (0.93, 2.05)
nent		1.16 (0.82, 1.64)
ement	•	1.41 (0.98, 2.03)
ent	_	2.63 (1.85, 3.74)
nent	→	1.13 (0.75, 1.71)
nent	→	1.43 (0.93, 2.19)
lvement	←	1.69 (1.19, 2.40)
nvolvement	→	0.90 (0.56, 1.44)
be	→	2.06 (1.21, 3.52)
ре	◆	1.11 (0.76, 1.62)
уре	•	2.31 (0.93, 5.60)
c subtype	→	2.77 (1.27, 6.01)
subtype	→	1.73 (0.85, 3.52)
ре	←	1.74 (0.93, 3.24)
.125	1	8

		RR (95% CI)
ker vs. never smoker		3.08 (2.06, 4.61)
9 vs. <25	+	1.88 (1.19, 2.96)
9 vs. <25		3.22 (1.98, 5.26)
. <25	_	• 6.60 (4.26, 10.23)
n² (yes vs. no)	→	1.72 (1.04, 2.85)
n² (yes vs. no)	•	3.18 (1.71, 5.90)
olecystectomy (yes vs. no)		3.45 (2.34, 5.08)
or radiographic gallstones (yes vs. no)	+	2.51 (1.69, 3.73)
.125	1	8
yes vs. no)		OR (95% CI)
-		0.52 (0.21, 1.28)
.25	1	4
OR: Odds ratio, RR: Relative risk		